Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Leiomyosarcoma 1

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × PTC596 × Clear all
NCT03206645 2024-04-23

PTC-001

University of Oklahoma

Phase 1 Completed
27 enrolled
Gynecologic

Ovarian Neoplasms

NCT03761095 2024-03-15

A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

PTC Therapeutics

Phase 1 Completed
41 enrolled
Sarcoma

Leiomyosarcoma

NCT02404480 2017-12-08

PTC596 in Patients With Advanced Solid Tumors

PTC Therapeutics

Phase 1 Completed
31 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡